HOOKIPA Pharma surges on cancer therapy deal with Roche
20/10/2022 12:59
** Shares of HOOKIPA Pharma Inc HOOK.O surge ~48% to $1.8
before the bell
** HOOKIPA and Roche Holding ROG.S to develop HB-700 and a
second undisclosed novel arenaviral immunotherapy to treat
different cancers urn:newsml:reuters.com:*:nGNX7rTwv8
** HOOKIPA to get $25 mln upfront cash and future
success-based milestone payments up to nearly $930 mln, plus
tiered royalties
** At current gains, stock poised to erase almost all YTD
losses
(Reporting by Pratik Jain)
((Pratik.Jain@thomsonreuters.com;))
Recent news on Hookipa Pharma
See all newsBrief: Hookipa Pharma Announces Sale Of Oncology Assets To Neotrail Therapeutics
Brief: Hookipa Pharma Announces Intention To Voluntarily Delist And Deregister Its Common Stock
Hookipa Pharma Inc Expected To Post A Loss Of $1.04 A Share: Earnings Preview
Brief: Poolbeg Pharma Says Hookipa Terminated Discussions On Proposed Merger
HOOKIPA Pharma Inc. (“HOOKIPA”) Statement regarding potential combination for Poolbeg Pharma plc (“Poolbeg”)